Pancreatic cancer device delivers chemo directly to tumor, aims to reduce side effects

NCT ID NCT07481383

Recruiting now Disease control Sponsor: Continuity Biosciences, LLC Source: ClinicalTrials.gov ↗

First seen Mar 27, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This early-phase study tests a new device that is surgically placed on the pancreas to deliver the chemotherapy drug gemcitabine directly to the tumor. The goal is to see if this approach is safe and tolerable for people with advanced pancreatic cancer that cannot be removed by surgery. About 12 participants will receive treatment for 8 weeks and be followed for 24 weeks total.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA NON-RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Michigan Health
RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact
West Virginia University
RECRUITING

Morgantown, West Virginia, 26506, United States

Contact

Conditions

Explore the condition pages connected to this study.

PANCREATIC ADENOCARCINOMA NON-RESECTABLE